Inhibition of Retinal Neovascularization by Intravitreal Injection of Human rPAI-1 in a Rat Model of Retinopathy of Prematurity

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 12, 2003, Pages 5423-5429

  Penn, John S ^a   Rajaratnam, Veera S ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; BUFFER; METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR;

AMBIENT AIR; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; INCUBATOR; INTERMETHOD COMPARISON; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PREMATURITY; PRIORITY JOURNAL; RAT; RETINA; RETINOPATHY; STAINING; ZYMOGRAPHY;

ANIMALS; ANIMALS, NEWBORN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GELATINASES; HUMANS; INFANT, NEWBORN; INJECTIONS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; SERINE PROTEINASE INHIBITORS; URINARY PLASMINOGEN ACTIVATOR; VITREOUS BODY;

EID: 0345282955     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.02-0804     Document Type: Article

References (48)

1. American Academy of Ophthalmology. Eye Care for the American People. (Information Statement). San Francisco: American Academy of Ophthalmology; 1987.
2. National Advisory Eye Council. Vision Research. A National Plan 1999-2003. Bethesda, MD: The National Institutes of Health.
3. Folkman J. Angiogenesis. In: Jaffe EA, ed. Biology of Endothelial Cells. Boston: Martinus Nijhoff Publishers; 1984:412-428.
4. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein. 1996;49:117-137.
5. Blasi F, Vassalli J-D, Dano K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol. 1987;104:801-804.
6. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Canc Res. 1985;44:139-266.
7. Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta. 1985;823:35-65.
8. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990;6:121-125.
9. Opdenakker G, Paeman L, Norga K, Masure S. Proteinase inhibition in invasive cancer therapy: four control levels of matrix degradation. Int J Cancer. 1997;70:628-630.
10. Penn JS, Rajaratnam VS, Collier RC, Clark AF. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2001;42:283-290.
11. Blei F, Wilson EL, Mignatti P, Rifkin DB. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol. 1993;155:568-578.
12. Ny T, Sawdy M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequencing of a cDNA coding for the human B-migrating endothelial cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA. 1986;83:6776-6780.
13. Loskutoff DJ, van Mourik LA, Erickson LA, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA. 1983;80:2956-2960.
14. Chielewska J, Ranby M, Wiman B. Kinetics of the inhibition of plasminogen activator by the plasminogen activator inhibitor. Biochem J. 1988;251:327-332.
15. 2 variation determines the severity of oxygen-induced retinopathy in newborn rats. Invest Ophthalmol Vis Sci. 1995;36:2063-2070.
16. Penn JS, Henry MM, Tolman, BL. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res. 1994;34:724-731.
17. Holmes JM, Duffner A. The effect of growth retardation on abnormal neovascularization in the oxygen exposed neonatal rat. Curr Eye Res. 1996;15:403-409.
18. Shafiee A, Roberts DD, Penn JS, Blake DA. Thrombospondin (TSP) peptides inhibit angiogenesis in retinal explant assay and rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2000;41:2378-2388.
19. Penn JS, Henry MM. Assessing retinal neovascularization in an animal model of proliferative retinopathy. Microvasc Res. 1996;51:126-130.
20. Zhang S, Leske DA, Uhl JR, Cockerill FR, Lanier WL, Holmes JM. Retinopathy associated with Enterococcus enteropathy in the neonatal rat. Invest Ophthalmol Vis Sci. 1999;40:1305-1309.
21. Holmes JM, Zhang S, Leske DA, Lanier WL. Metabolic acidosis-induced retinopathy in the neonatal rat. Invest Ophthalmol Vis Sci. 1999;40:804-809.
22. Holmes JM, Zhang S, Leske DA, Lanier WL. The effect of carbon dioxide on oxygen-induced retinopathy in the neonatal rat. Curr Eye Res. 1997;16:725-732.
23. Holmes JM, Zhang S, Leske DA, Lanier WL. Carbon dioxide-induced retinopathy in the neonatal rat. Curr Eye Res. 1998;17:608-616.
24. Zhang S, Leske DA, Holmes JM. Neovascularization grading methods in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2000;41:887-891.
25. Grant MB, Spoerri PE, Player DW, Bush DM, Ellis EA, Caballero S, Robison WG. Plasminogen activator inhibitor (PAI)-1 overexpression in retinal microvessels of PAI-1 transgenic mice. Invest Ophthalmol Vis Sci. 2000;41:2296-2302.
26. Maurice DM, Mishima S. Ocular pharmacokinetics. In: Sears, ML, ed. Pharmacology of the Eye. Handbook of Experimental Pharmacology. Vol. 69. Berlin, New York: Springer-Verlag; 1984:72-75.
27. Steen B, Sejersen S, Berglin L, Seregard S, Kvanta A. Matrix Metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1998;39:2194-2200.
28. Das A, McLamore A, Song W, McGuire PG. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol. 1999;117:498-503.
29. Karelina TV, Goldberg GI, Elsen AZ. Matrix metalloproteinases in blood vessel development in human fetal skin and in cutaneous tumors. J Invest Dermatol. 1995;105:411-417.
30. Puyraimond A, Weitzman JB, Babiole E, Menashi S. Examining the relationship between the gelatinolytic balance and the invasive capacity of endothelial cells. J Cell Sci. 1999;112:1283-1290.
31. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064-3073.
32. Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res. 2000;70:419-428.
33. McQuibban GA, Gong J-H, Tam EM, McCulloch CAG, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000;289:1202-1206.
34. Levi E, Fridman R, Miao H-Q, Ma Y-C, Yayon A, Vlodavsky I. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA. 1996;93:7069-7074.
35. Levin EG, Santell L. Conversion of the active to latent plasminogen activator inhibitor from human endothelial cells. Blood. 1987;70:1090-1096.
36. Wiman B, Almquist A, Sigurdardottier O, Lindahl T. Plasminogen activator inhibitor-1 (PAI-1) is bound to vitronectin in plasma. FEBS Lett. 1988;242:125-128.
37. Friedlander M, Theesfeld CL, Sugita M. Involvement of integrins alpha v/beta 3 and alpha v/beta 5 in ocular neovascular diseases. Proc Natl Acad Sci USA. 1996;93:9764-9769.
38. Hammes H-P, Brownlee M, Jonczyk A. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med. 1996;2:529-533.
39. Kjoller L, Kanse SM, Kirkegaard T, et al. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res. 1997;232:420-429.
40. Germer M, Kanse SM, Kirkegaard T, et al. Kinetic analysis of integrin-dependent cell adhesion on vitronectin: the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides. Eur J Biochem. 1998;253:669-674.
41. Pepper MS, Vassalli JD, Wilks JW, Schweigerer L, Orci L, Montesano R. Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J Cell Biochem. 1994;55:419-434.
42. Flaumenhaft R, Rifkin DB. The extracellular regulation of growth factor action. Mol Biol Cell. 1992;3:1057-1065.
43. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2:737-744.
44. Aiello LP, Pierce EA, Foley ED. Suppression of retinal neovascularization in vivo by inhibition of VEGF using a VEGF-receptor chimeric protein. Proc Natl Acad Sci USA. 1995;92:10457-10461.
45. Robinson GS, Pierce EA, Rook SL, Foley E. Webb R. Smith LE. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA. 1996;93:4851-4856.
46. Adamis AP, Shima DT, Tolentino MJ. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996;114:66-71.
47. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization by retinal ischemia in pigs by PKCβ inhibition with LY333531. Invest Ophthalmol Vis Sci. 1998;39:171-179.
48. Bullard LE, Qi X, Penn JS. Role for extracellular signal-responsive kinase-1 and -2 in retinal angiogenesis. Invest Ophthalmol Vis Sci. 2003;44:1722-1731.